Free Trial

Tandem Diabetes Care (TNDM) Stock Forecast & Price Target

Tandem Diabetes Care logo
$22.14 +0.39 (+1.79%)
Closing price 04:00 PM Eastern
Extended Trading
$22.15 +0.01 (+0.05%)
As of 04:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tandem Diabetes Care - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
4
Buy
14

Based on 18 Wall Street analysts who have issued ratings for Tandem Diabetes Care in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 18 analysts, 4 have given a hold rating, and 14 have given a buy rating for TNDM.

Consensus Price Target

$52.31
136.28% Upside
According to the 18 analysts' twelve-month price targets for Tandem Diabetes Care, the average price target is $52.31. The highest price target for TNDM is $75.00, while the lowest price target for TNDM is $25.00. The average price target represents a forecasted upside of 136.28% from the current price of $22.14.
Get the Latest News and Ratings for TNDM and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Tandem Diabetes Care and its competitors.

Sign Up

TNDM Analyst Ratings Over Time

TypeCurrent Forecast
2/29/24 to 2/28/25
1 Month Ago
1/30/24 to 1/29/25
3 Months Ago
12/1/23 to 11/30/24
1 Year Ago
3/1/23 to 2/29/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
14 Buy rating(s)
15 Buy rating(s)
14 Buy rating(s)
4 Buy rating(s)
Hold
4 Hold rating(s)
3 Hold rating(s)
4 Hold rating(s)
8 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$52.31$53.81$54.25$35.33
Forecasted Upside136.28% Upside48.00% Upside77.11% Upside32.68% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Hold

TNDM Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

TNDM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Tandem Diabetes Care Stock vs. The Competition

TypeTandem Diabetes CareMedical CompaniesS&P 500
Consensus Rating Score
2.83
2.82
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside145.40% Upside29,012.36% Upside15.72% Upside
News Sentiment Rating
Positive News

See Recent TNDM News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
2/28/2025Sanford C. Bernstein
3 of 5 stars
L. Hambright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform$35.00 ➝ $25.00+14.94%
2/27/2025Royal Bank of Canada
4 of 5 stars
S. Singh
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOutperform ➝ Outperform$65.00 ➝ $55.00+147.41%
2/27/2025Robert W. Baird
2 of 5 stars
Jeff Johnson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetNeutral ➝ Neutral$37.00 ➝ $33.00-1.76%
2/26/2025Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
William Plovanic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$63.00 ➝ $63.00+86.24%
12/11/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$57.00 ➝ $50.00+45.48%
12/2/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeEqual Weight ➝ Overweight$45.00 ➝ $45.00+46.91%
11/8/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$58.00 ➝ $60.00+92.86%
10/4/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Roman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$46.00+13.69%
8/2/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Antalffy
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
8/2/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$50.00 ➝ $55.00+31.86%
8/2/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$50.00 ➝ $55.00+29.35%
6/10/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$47.00 ➝ $58.00+18.73%
5/30/2024Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$60.00+15.94%
5/22/2024Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$60.00 ➝ $75.00+47.17%
5/22/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$45.00 ➝ $55.00+11.52%
4/25/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Kratky
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform
4/25/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform$34.00 ➝ $45.00+28.13%
10/2/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$47.00 ➝ $45.00+116.66%
8/4/2023TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$52.00 ➝ $34.00+2.87%
6/13/2023Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$74.00 ➝ $50.00+93.12%
5/5/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Underperform$45.00 ➝ $33.00-12.02%
4/24/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 05:02 PM ET.


TNDM Forecast - Frequently Asked Questions

According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for Tandem Diabetes Care is $52.31, with a high forecast of $75.00 and a low forecast of $25.00.

18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last year. There are currently 4 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TNDM shares.

According to analysts, Tandem Diabetes Care's stock has a predicted upside of 136.28% based on their 12-month stock forecasts.

Over the previous 90 days, Tandem Diabetes Care's stock had 1 upgrade and 1 downgrade by analysts.

Tandem Diabetes Care has been rated by research analysts at Canaccord Genuity Group, Citigroup, Morgan Stanley, Robert W. Baird, Royal Bank of Canada, and Sanford C. Bernstein in the past 90 days.

Analysts like Tandem Diabetes Care less than other "medical" companies. The consensus rating score for Tandem Diabetes Care is 2.78 while the average consensus rating score for "medical" companies is 2.82. Learn more on how TNDM compares to other companies.


This page (NASDAQ:TNDM) was last updated on 2/28/2025 by MarketBeat.com Staff
From Our Partners